Therefore, we attempted to develop a new ADC, Y-TR1, which has a higher efficiency of anti-tumor action because triptolide was conjugated with humanized anti-human CD26 monoclonal antibody, YS110, with anti-tumor effects via the suppression of POLR2A transcription, retarded G2/M cell cycling, and antibody-dependent cell-mediated cytotoxicity (ADCC) / complement-dependent cytotoxicity (CDC) [13,23]. The gene discussed is POLR2A; the disease is neoplasm.